ERBB2 and breast carcinoma: Despite medical advances in the treatment of this type of breast cancer, approximately 22%–25% of HER-2-positive metastatic breast cancer patients have congenital or acquired drug resistance, which is associated with significant morbidity and mortality (Choong et al., 2020).